Antidepressants and the risk of suicide in young persons - prescription trends and toxicological analyses

Acta Psychiatrica Scandinavica

Volumn 129, Issue 4, 2014, Pages 296-302

  Isacsson, G ^a   Ahlner, J ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Forensic Toxicology and Forensic Genetics National Board of Forensic Medicine ^*  (Sweden)

Author keywords

Adolescent; Antidepressants; Forensic toxicology; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; BLACK BOX WARNING; CHILD; CONTROLLED STUDY; DRUG PACKAGING; DRUG SAFETY; DRUG USE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MENTAL PATIENT; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SUICIDE; SWEDEN; TREND STUDY; YOUNG ADULT; AUTOPSY; COMPARATIVE STUDY; DEPRESSION; EPIDEMIOLOGY; FEMALE; MALE; RISK; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; AUTOPSY; CHILD; DEPRESSION; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; RISK; SUICIDE; SWEDEN; YOUNG ADULT;

EID: 84896048998     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12160     Document Type: Article

References (31)

1. Mann JJ, Emslie G, Baldessarini RJ et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006;31:473-492.
2. Bridge JA, Kelleher KJ. The 2004 FDA warning on antidepressant suicidality risk changed outpatient treatment patterns for young people with new-onset depression. Evid Based Ment Health 2011;14:42.
3. Gibbons RD, Brown CH, Hur K et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164:1356-1363.
4. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009;66:633-639.
5. Nemeroff CB, Kalali A, Keller MB et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007;64:466-472.
6. Bergen H, Hawton K, Murphy E et al. Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds. Br J Clin Pharmacol 2009;68:618-629.
7. Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008;178:1005-1011.
8. Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ. Suicide trends among youths aged 10 to 19 years in the United States, 1996-2005. JAMA 2008;300:1025-1026.
9. Donaldson AE, Larsen GY, Fullerton-Gleason L, Olson LM. Classifying undetermined poisoning deaths. Inj Prev 2006;12:338-343.
10. Henriksson S, Boethius G, Hakansson J, Isacsson G. Indications for and outcome of antidepressant medication in a general population: a prescription database and medical record study, in Jamtland county, Sweden, 1995. Acta Psychiatr Scand 2003;108:427-431.
11. Isacsson G, Holmgren A, Osby U, Ahlner J. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatr Scand 2009;120:37-44.
12. Jick H, Kaye JA, Jick SS. Antidepressants and the Risk of Suicidal Behaviors. JAMA 2004;292:338-343.
13. Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004;65:915-918.
14. Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Markham Piper T, Galea S. Antidepressants and youth suicide in New York City, 1999-2002. J Am Acad Child Adolesc Psychiatry 2006;45:1054-1058.
15. Leon AC, Solomon DA, Li C et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 2011;72:580-586.
16. Moskos M, Olson L, Halbern S, Keller T, Gray D. Utah youth suicide study: psychological autopsy. Suicide Life Threat Behav 2005;35:536-546.
17. Sondergard L, Kvist K, Andersen PK, Kessing LV. Do antidepressants precipitate youth suicide?: a nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry 2006;15:232-240.
18. Dudley M, Goldney R, Hadzi-Pavlovic D. Are adolescents dying by suicide taking SSRI antidepressants? A review of observational studies. Australas Psychiatry 2010;18:242-245.
19. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14, 857 suicides. Acta Psychiatr Scand 2005;111:286-290.
20. Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008;336:542-545.
21. Wheeler BW, Metcalfe C, Martin RM, Gunnell D. International impacts of regulatory action to limit antidepressant prescribing on rates of suicide in young people. Pharmacoepidemiol Drug Saf 2009;18:579-588.
22. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-339.
23. March J, Silva S, Petrycki S et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-820.
24. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-1345.
25. Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand 2007;115:184-195.
26. Parker G. Evaluating treatments for the mood disorders: time for the evidence to get real. Aust N Z J Psychiatry 2004;38:408-414.
27. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry 2000;157:327-337.
28. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572-579.
29. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:580-587.
30. Isacsson G, Adler M. Randomized Clinical Trials underestimate the efficacy of antidepressants in less severe depression. Acta Psychiatr Scand 2012;125:453-459.
31. Ghaemi SN, Vohringer PA, Whitham EA. Antidepressants from a public health perspective: re-examining effectiveness, suicide, and carcinogenicity. Acta Psychiatr Scand 2013;127:89-93.